Mariusz L Hartman

13PUBLICATIONS
8CO-AUTHORS
Predictive and prognostic markersApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Molecular targetsOncology and carcinogenesis not elsewhere classifiedBiologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (13)

|Jul 28, 2025
Balancing between cuproplasia and copper-dependent cell death: molecular basis and clinical implications of ATOX1 in cancer.

Justyna Suwara, Mariusz L Hartman

|Mar 20, 2025
Dual role of interferon-gamma in the response of melanoma patients to immunotherapy with immune checkpoint inhibitors.

Piotr Wawrzyniak, Mariusz L Hartman

|Dec 18, 2024
Tipping the balance of cell death: alternative splicing as a source of MCL-1S in cancer.

Mariusz L Hartman

|Oct 14, 2023
Pro-Apoptotic Activity of MCL-1 Inhibitor in Trametinib-Resistant Melanoma Cells Depends on Their Phenotypes and Is Modulated by Reversible Alterations Induced by Trametinib Withdrawal.

Mariusz L Hartman, Paulina Koziej, Katarzyna Kluszczyńska

|May 13, 2023
Trametinib-Resistant Melanoma Cells Displaying MITFhigh/NGFRlow/IL-8low Phenotype Are Highly Responsive to Alternating Periods of Drug Withdrawal and Drug Rechallenge.

Paulina Koziej, Katarzyna Kluszczynska, Mariusz L Hartman

|Apr 08, 2023
BCL-G: 20 years of research on a non-typical protein from the BCL-2 family.

Mariusz L Hartman, Malgorzata Czyz

Pageof 3

Frequent Collaborators

9 joint publications

Malgorzata Czyz

2 joint publications

Aleksandra Mielczarek-Lewandowska

2 joint publications

Malgorzata Sztiller-Sikorska

2 joint publications

Katarzyna Kluszczynska